Mira Pharmaceuticals, INC 8-K filings
NASDAQ
Mira Pharmaceuticals has received a delisting notice from Nasdaq due to its stock price falling below $1.00, but the company is working to regain compliance while also reporting positive preclinical results for its MIRA-55 compound.
NASDAQ
MIRA Pharmaceuticals has amended its employment agreement with CFO Michelle Yanez, reducing her annual base salary to $137,500 and setting a minimum 30-hour work week.
NASDAQ
MIRA Pharmaceuticals has amended its employment agreement with CEO Erez Aminov, increasing his base salary and enhancing severance benefits under certain termination scenarios.
NASDAQ
Mira Pharmaceuticals has announced a significant restructuring of its board of directors and changes in key personnel, including the appointment of new board members and a new Chief Scientific Advisor.
NASDAQ
8-K: Mira Pharmaceuticals Discovers New Molecule, MIRA-55, with Enhanced Potency Over Original Candidate
Mira Pharmaceuticals has discovered that a compound used in previous pre-clinical studies, initially believed to be MIRA1a, is actually a new molecule called MIRA-55, which shows enhanced potency and potential for efficacy.
NASDAQ
Christos Nicholoudis, Esq. has resigned from the Board of Directors and as part-time General Counsel of Mira Pharmaceuticals, effective January 15, 2024.